Elanco Animal Health Incorporated (ELAN)

Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Elanco Animal Health Incorporated (ELAN) or U.S. Physical Therapy (USPH). But which of these two companies is the best option for those looking for undervalued stocks?

ELAN, DINO and EMBC made it to the Zacks Rank #1 (Strong Buy) value stocks list on October 6, 2025.

GREENFIELD, Ind. , Oct. 1, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2025 financial results on Wednesday, November 5, 2025.

Elanco Animal Health (ELAN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

FDA now concludes "t he totality of evidence supports removal of the risk of fatal vaccine-induced disease from modified live virus vaccines from the labeling"i Further evaluation of supplemental scientific data drove this FDA update; data now peer-reviewed and published Real-world success and experiences from dermatologists and general practice veterinarians around the U.S. and the world further demonstrate Zenrelia's efficacy INDIANAPOLIS , Sept. 23, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced important updates to the U.S. Zenrelia label, following the Food and Drug Administration (FDA) review of supplemental scientific data.

Elanco Animal Health Incorporated (NYSE:ELAN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 8:30 AM EDT Company Participants Jeffrey Simmons - President, CEO & Director Robert VanHimbergen - Executive VP & CFO Conference Call Participants Erin Wilson Wright - Morgan Stanley, Research Division Presentation Erin Wilson Wright Equity Analyst Hi. Good morning, everyone.

NEW YORK , Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE: ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (XNYS: BHLB) is acquiring Brookline Bancorp in a deal expected to be completed soon, pending final closing conditions.

GREENFIELD, Ind. , Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 23rd Annual Global Healthcare Conference, September 8-9, 2025.

Elanco Animal Health Incorporated (NYSE:ELAN ) Q2 2025 Earnings Conference Call August 7, 2025 9:00 AM ET Company Participants Jeffrey N. Simmons - President, CEO & Director Robert M.

I rate Elanco Animal Health Incorporated shares a Buy with a $20 fair value, driven by strong innovation and recent operational improvements. Elanco's focus on innovative products like Zenrelia and strategic divestitures positions it for growth in both companion and farm animal markets. Strong Q2 results, raised full-year guidance, and increased innovation revenue targets support my positive outlook for future growth.

Elanco Animal Health Incorporated ELAN reported second-quarter 2025 results on Thursday, posting adjusted earnings per share of 26 cents, down 13% year over year.

Although the revenue and EPS for Elanco Animal Health (ELAN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.2 per share. This compares to earnings of $0.3 per share a year ago.

Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Second Quarter  2025 Financial Results: Revenue of $1,241 million, an increase of 5% year-over-year; 8% organic constant currency growth Reported Net Income of $11 million, Adjusted Net Income of $131 million Adjusted EBITDA of $238 million; Adjusted EBITDA Margin of 19.2%  Reported EPS of $0.02, Adjusted EPS of $0.26 Net leverage ratio of 4.0x Adjusted EBITDA Full Year 2025 Guidance: Raising revenue guidance to $4,570 to $4,620 million; expect accelerating organic constant currency revenue growth of 5% to 6% vs. 3% in 2024 Raising 2025 innovation revenue target by $60 million to $720 to $800 million Reported Net Loss of $(38) to $(14) million, raising guidance for Adjusted EBITDA to $850 to $890 million Reported Loss Per Share of $(0.08) to $(0.03), raising guidance for Adjusted EPS to $0.85 to $0.91  Outlook incorporates current estimate for net tariff impact and dynamic landscape, more than offset by a strong first half performance and foreign exchange tailwinds to revenue versus prior expectations  Increasing expected gross debt paydown range to $500 to $550 million in 2025 2025 year-end net leverage ratio target improved to 3.8x to 4.1x, enabled by year-to-date execution and disciplined working capital management GREENFIELD, Ind.